(0.32%) 5 116.11 points
(0.32%) 38 363 points
(0.35%) 15 983 points
(-0.94%) $83.06
(5.56%) $2.03
(0.34%) $2 355.10
(0.42%) $27.65
(4.02%) $959.15
(-0.25%) $0.932
(-0.40%) $10.98
(-0.56%) $0.796
(1.69%) $93.43
Live Chart Being Loaded With Signals
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD)...
Stats | |
---|---|
本日の出来高 | 3.00 |
平均出来高 | 4.22M |
時価総額 | 0.00 |
EPS | $0 ( 2021-07-29 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 59.23 |
ATR14 | $1.935 (1.06%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2021-07-21 | Coughlin Christopher J | Sell | 42 347 | Common Stock, par value $.0001 per share |
2021-07-21 | Coughlin Christopher J | Sell | 2 294 | Option to Purchase Common Stock |
2021-07-21 | Coughlin Christopher J | Sell | 2 706 | Option to Purchase Common Stock |
2021-07-21 | Coughlin Christopher J | Sell | 2 343 | Option to Purchase Common Stock |
2021-07-21 | Sarin Aradhana | Sell | 120 253 | Common Stock, par value $.0001 per share |
INSIDER POWER |
---|
0.00 |
Last 100 transactions |
Buy: 1 094 307 | Sell: 1 860 897 |
ボリューム 相関
Alexion Pharmaceuticals, 相関
10 最も負の相関 | |
---|---|
FUV | -0.983 |
MESA | -0.979 |
MBIO | -0.979 |
JG | -0.977 |
MLKN | -0.975 |
RENT | -0.974 |
NXTC | -0.974 |
GERN | -0.974 |
ASRV | -0.973 |
CNTY | -0.973 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Alexion Pharmaceuticals, 相関 - 通貨/商品
Alexion Pharmaceuticals, 財務諸表
Annual | 2020 |
収益: | $6.07B |
総利益: | $5.52B (90.88 %) |
EPS: | $2.74 |
FY | 2020 |
収益: | $6.07B |
総利益: | $5.52B (90.88 %) |
EPS: | $2.74 |
FY | 2019 |
収益: | $4.99B |
総利益: | $4.60B (92.10 %) |
EPS: | $10.77 |
FY | 2018 |
収益: | $4.13B |
総利益: | $3.76B (90.94 %) |
EPS: | $0.348 |
Financial Reports:
No articles found.
Alexion Pharmaceuticals,
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。